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SUMMARY
Aims：This study was the retrospective analysis of the previous study named as APPLE study （study of 
combination effect of AlogliPtin and lansoPrazoLE on glycemic control in patients with type 2 diabetes）, in 
which the effect of the combination therapy of alogliptin （a dipeptidyl peptidase-4 inhibitor, DPP4-I） and 
lansoprazole （a proton pump inhibitor, PPI） was compared with alogliptin mono-therapy without PPI on 
glycemic control in a randomized open-label study design. The aim of this study was to investigate whether 
“so called” legacy effect of proton pump inhibitor on glycemic control is observed.
Patients and Methods：In the patients that participated in the APPLE study （3 months observation；to-
tal：100 patients）, the patients who continued the intake of alogliptin at least more than 1 year after the 
registration（enrollment）in APPLE study was evaluated on glycemic control retrospectively. As a rule, the 
administration of lansoprazole in combination group was discontinued after the finish of 3 months- of the 
APPLE study. Twenty-six patients in the alogliptin mono-therapy group and 26 patients in combination 
group met the requirement in this analysis. Mean observation periods were respectively 16 months. In these 
patients, the number of patients in whom all diabetic drugs were not changed in observation-period was re-
spectively 18 in alogliptin mono-therapy group and 17 in combination group.
Results：The decrease of HbA1c was maintained also after long term observation （16 months） in both 
alogliptin mono-therapy and combination groups （the decrease was respectively −1.054±0.548 and −
1.123±0.723％）, which was similar compared with that observed in 3 months-APPLE study. There were no 
significant differences in change of HbA1c and fasting plasma glucose （FPG） at the time in enrollment of 
APPLE study and at final visit （approximately 16 weeks） between these groups. The significant difference 
in change of HbA1c and FPG was not found also between alogliptin mono-therapy and combination group 
in the subgroup of patients where all diabetic drugs were unchanged during observation period.
Conclusion：This study found that the legacy effect of PPI on glycemic control was not apparent more 
than 9 months after the APPLE study. Based on the results in the previous APPLE study and in this cur-
rent retrospective study, we concluded that the 
add-on effect of PPI for DPP4-I on glycemic con-
trol in patients with type 2 diabetes is not clinical-
ly apparent.
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INTRODUCTION
Gastrin is a peptide hormone produced mainly in the 
G cells of the pyloric antrum of the stomach 1,2）. The 
main role of gastrin is the promotion of gastric acid se-
cretion from the parietal cells of the stomach. Gastrin 
can also act as a growth factor and stimulate gastric 
cell proliferation3,4）. In an animal model in which pan-
creatic tissue remodeling is promoted, it is reported 
that gastrin increases b  cell neogenesis in the pancre-
atic ductal complex5,6）. Although the effect of gastrin 
on adult b  cell neogenesis appears to be observed only 
during pancreatic tissue remodeling5,7）, interestingly, in 
combination with other hormones, such as glucagon-
like peptide-1（GLP-1）, gastrin becomes to be able to 
enhance b  cell neogenesis in ductal cells, even when 
this agent is added in animal models, such as db/db 
mice （a model of type 2 diabetes） and non-obese dia-
betic （NOD） mice （a model of type 1 diabetes）8,9）. In 
these models, pancreatic remodeling is not necessarily 
occurring. Although gastrin cannot be administrated 
orally, oral proton pump inhibitors（PPIs）, which are 
widely used clinically for the treatment of gastro-
esophageal reflex disease, gastritis due to excess stom-
ach acid, and gastric ulcers10）, indirectly elevate serum 
gastrin levels 11〜16）. It is also reported that, in NOD 
mice, the combination therapy of a PPI with a dipepti-
dyl peptidase-4 inhibitor（DPP4-I）, which blocks deg-
radation of GLP-1 by DPP4 resulting in the elevation 
of serum active GLP-1 levels, was more effective on 
glycemic control than that of each drug used in mono-
therapy17）. Furthermore, a recent study showed that 
combination therapy with exendin-4 （a GLP-1 recep-
tor agonist） and omeprazole （a PPI） more effectively 
improved glycemic control over that of each drug used 
separately in db/db mice18）. These results suggest the 
possibility that combination therapy, including a PPI 
and a GLP-1 receptor agonist （or a DPP4-I）, may be 
more effective for inhibition of progression in both type 
1 and type 2 diabetes, and may more effectively im-
prove glycemic control, compared with that in those 
patients using a PPI or GLP-1 receptor agonist （or 
DPP4-I） as mono-therapy. Although many clinical 
studies demonstrate that PPIs improved glycemic con-
trol in patients with type 2 diabetes19〜25）with some in 
disagreement26,27）, there are no reports investigating 
the effect of a combination therapy of a DPP4-I and a 
PPI in these patients （for review see reference28）. 
Based on these backgrounds, we recently investigated 
the effect of a combination therapy of alogliptin （a 
DPP4-I） and lansoprazole  （a PPI） compared with alo-
gliptin mono-therapy on glycemic control in patients 
with type 2 diabetes in a randomized open-label study 
named as APPLE （study of combination effect of Alo-
gliPtin and lansoPrazoLE on glycemic control in pa-
tients with type 2 diabetes）29）. Contrary to our expec-
tation, the effect of the combination therapy on 
glycemic control was equal to that of alogliptin mono-
therapy during a 3-month study period. However, if 
the expected effect of this combination therapy on gly-
cemic control is based partially on the increased b  cell 
mass by neogenesis in ductal cells, the effect on glyce-
mic control might be observable only after a relatively 
long term；i.e., “so called” legacy effect. Therefore, we 
performed a retrospective analysis on the patients in 
the APPLE study after its completion. At the end of 
the 3-month APPLE study, the patients in combina-
tion therapy with alogliptin and lansoprazole discontin-
ued the lansoprazole as a rule. In the patients who 
were enrolled in APPLE study and who continued tak-
ing alogliptin, the glycemic control was evaluated more 
than 9 months after the finish of the study.
PATIENTS and METHODS
This study was the retrospective analysis of the our 
previous study named as APPLE study. In the APPLE 
study, the effect of the combination therapy of alo-
gliptin and lansoprazole compared with alogliptin mo-
no-therapy without PPI on glycemic control was pro-
spectively evaluated in a randomized open-label study 
design. All subjects gave informed consent for inclu-
sion in the APPLE study. The APPLE study was ap-
proved by the Local Ethics Committee in Dokkyo 
Medical University Koshigaya Hospital and was per-
formed according to the guidelines of the Declaration 
of Helsinki. APPLE study has been registered at UMIN 
0000009445. For the details on the APPLE study, see 
reference29）. This retrospective analysis of APPLE 
study was approved by the Bioethics Committee in 
Dokkyo Medical University Koshigaya Hospital（Ap-
proval number：Koshigaya-27002）
In the patients that participated in APPLE study（to-
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tal：100 patients）, the patients who continued the in-
take of alogliptin at least more than 1 year after the 
registration （enrollment） in the APPLE study were 
evaluated on glycemic control retrospectively. Twen-
ty-six patients in combination group and 26 patients in 
alogliptin mono-therapy group met the inclusion re-
quirements. The number of patients in whom sulfonyl-
urea （SU） was reduced after the finish of the APPLE 
study was 6 in alogliptin mono-therapy group and 5 in 
combination group. Mean observation periods were 
16 months in both groups. The clinical features at base-
line of the patients in both alogliptin mono-therapy 
group and combination group who met the require-
ments are summarized in Table 1. There were no sig-
nificant differences in age, BMI, FPG, HbA1c between 
these groups. The number of patients in whom all dia-
betic drugs were not changed during observation-peri-
od was 18 in alogliptin mono-therapy group and 17 in 
combination group. In the combination group, although, 
as a rule, the patients discontinued the intake of lanso-
prazole at the time point of the finish of APPLE study 
as previously described, 3 patients continued taking 
lansoprazole at their request. These patients had had 
mild gastrointestinal symptoms before enrollment of 
the APPLE study, and after taking lansoprazole these 
symptoms improved.
Statistical methods. The two time points for each pa-
rameter for an individual were compared using a 
paired t-test. Comparisons between the two groups 
were made using an unpaired t-test for normally dis-
tributed data（confirmed by a c 2 test）；a Student t-test 
or a Welch t-test was chosen based on the homogenei-
ty of variance calculated by an F-test. Comparisons of 
hemoglobin A1c （HbA1c） and fasting plasma glucose
（FPG） in alogliptin- and those in alogloptin with lanso-
prazole-treated patients for changes from baseline 
were assessed using an analysis of variance （ANCO-
VA） model with treatment as fixed effects and the cor-
responding baseline value as a covariate. For HbA1c 
and FPG, least square （LS） mean difference were esti-
mated for the comparison of alogliptin and alogliptin 
with lansoprazole. A P value of less than 0.05 was ac-
cepted as indicating statistical significance （two-sid-
ed）.
RESULTS
Significant decreases in the HbA1c and FPG levels 
were obtained in the alogliptin mono-therapy group（n
＝26）（7.761±0.6020 to 6.707±0.580％，P＜0.0001 in 
HbA1c；161.8±37.1 to 138.4±42.1 mg/dL, P＝0.0042 
in FPG）. A significant decrease in HbA1c and a ten-
dency toward a decrease in FPG levels were observed 
in the combination treatment group（n＝26）（7.819±
0.5959 to 6.696±0.6526％，P＜0.0001 in HbA1c；164.2
±38.6 to 152.7±37.8 mg/dL, P＝0.1414 in FPG）. How-
ever, there was no significant difference in the change 
in both HbA1c and FPG levels at the initiation of ther-
apy and at the final visit in the observation-period be-
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Table 1　Clinical features at baseline in alogliptin and alogliptin with lansoprazole groups
Alogliptin Alogliptin＋lansoprazole P values
No.（male/female） 26（13/13） 26（13/13） ─
Age（year） 66.9±8.9 64.4±8.4 0.3021
BMI（kg/m2） 23.7±3.5 24.8±3.6 0.2842
FPG（mg/dL） 162.7±37.7 164.2±38.6 0.8850
HbA1c（％） 7.8±0.6 7.8±0.6 0.7299
Diabetic Therapy
SU S1/S2/S3 4/11/5 8/8/2
Metformin 2 2
AGI 1 3
Pioglitazone 0 1
None 3 2
BMI：body mass index, FPG：fasting plasma glucose, HbA1c：hemoglobin A1c, SU：
sulfonylurea, AGI：alfa-glucosidase inhibitor
Data are expressed as mean ±SD. P：p value, S1：SU alone, S2：SU and/or metformin, 
pioglitazone, AGI. S3：SU, and/or pioglitazone, AGI，
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group and −1.021±0.114％ in the combination group
（P＝0.5483）. Similarly, the LS mean differences with 
SE of FPG were -18 .6±8.4 mg/dL in the alogliptin 
mono-therapy group and -9.5±8.6 mg/dL in the com-
bination group （P＝0.4530）（Figure 2A, B）.
Furthermore, in the combination group in this sub-
group, when the patients were divided into 2 groups in 
whom lansoprazole was discontinued （n＝14）, and in 
whom lansoprazole was continued at the patients’ re-
quest（n＝3）, a significant decrease in both HbA1c and 
FPG levels was obtained in the discontinued group
（7.74±0.47 to 6.91±0.88％，P＝0.0002 in HbA1c；
159.1±42.0 to 131.3±26.6 mg/dL, P＝0.0067 in FPG）. 
In the continued group in this subgroup, HbA1c was 
significantly decreased （7.73±0.416 to 6.866±0.321
％，P＝0.0270）, while no significant decrease in FPG 
was obtained （189.3±20.6 to 140.0±39.7 mg/dL, P＝
0.2198）. The LS mean differences with SE of HbA1c at 
the initial and final observation points were −1.100±
0.542％ in the discontinued group and -0.667±0.603％ 
in the continued group （P＝0.2515）. Similarly, the LS 
mean differences with SE of FPG were −3 . 6±
10 .4 mg/dL in the discontinued group and −35 .1±
23.2 mg/dL in the continued group （P＝0.2399）（Fig 
3A, 3B）. The time series effect on HbA1c in the pa-
tients who continued to take alogliptin for more than 1 
tween the two groups using ANCOVA. The LS mean 
differences with standard error（SE）of HbA1c at both 
the initial and final observation points were −1.054±
0.548％ in the alogliptin mono-therapy group and −
1.123±0.723％ in the combination group（P＝0.8079）. 
Similarly, the LS mean differences with SE of FPG was 
−23 .5±38 .0 mg/dL in the alogliptin mono-therapy 
group and −11 . 5±38 . 7 mg/dL in the combination 
group（P＝0.1826）（Figure 1A, B）. In a subgroup in 
which all diabetic drugs were not changed during the 
observation period（18 patients in the alogliptin mono-
therapy group and 17 in the combination group）, there 
was a significant decrease in HbA1c and FPG levels in 
the alogliptin mono-therapy group（7.666±0.4887 to 
6.744±0.5903％，P＜0.0001 in HbA1c；166.5±36.2 to 
147.4±39.4 mg/dL, P＝0.0312 in FPG）. In the combi-
nation group in the subgroup, HbA1c was significantly 
reduced （7 .741±0 .4545 to 6 . 718±0 .6921％， P＜
0.0001）, but no change in FPG was found（164.4±40.4 
to 155.4±43.8 mg/dL, P＝0.3519）. There was no sig-
nificant difference in the change in both HbA1c and 
FPG levels at initiation of therapy and at the final visit 
in the observation period between the two groups us-
ing ANCOVA. The LS mean differences with SE of 
HbA1c at both the initial and final observation points 
were −0.924±0.111％ in the alogliptin mono-therapy 
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Fig. 1　The effect on HbA1c （A） and FPG （B） by therapy
In Fig1-5, patients in alogliptin group continued alogliptin-intake during 16 months-observation periods and 
patients in combination group continued alogliptin-intake during 16 months-observation periods and, as a 
rule, discontinued lansoprazole-intake 3 months after the initiation of intake of lansoprazole except for 4 
patients who continued lansoprazole-intake because of patient’s request.
Long term evaluation of alogliptin and lansoprazole
soprazole （a PPI） with the alogliptin mono-therapy on 
glycemic control for 3 months in patients with type 2 
diabetes29）. Contrary to our expectation, the effect of 
the combination therapy on glycemic control was equal 
to that of the alogliptin mono-therapy. However, be-
cause the effect on glycemic control by PPI together 
with DPP4-I might become apparent only after a rela-
tively long-term use based in part on the expected in-
year after enrollment in the APPLE study and in the 
subgroup patients where all diabetic drugs were not 
changed during the observation period is shown in Fig. 
4A, B, and 5A, B.
DISCUSSION
In the APPLE study, we compared the effect of the 
combination therapy of alogliptin （a DPP4-I） and lan-
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Fig. 2　 The effect on HbA1c （A） and FPG （B） by therapy in a subgroup in which all diabetic drugs were 
not changed in observation-periods.
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Fig. 3　 The effect on HbA1c （A） and FPG （B） by therapy in combination group in a subgroup in which all 
diabetic drugs were not changed in observation-periods：Comparison with patients with （n＝3） and 
without （n＝14） lansoprazole.
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the “so called” legacy effect on glycemic control by 
PPI together with DPP4-I is not apparent at least clini-
cally in patients with type 2 diabetes. It is difficult to 
explain exactly the reason for the negative results of 
this APPLE study and the additional retrospective 
analysis, because in animal models the synergic effect 
of the combination of PPI and DPP4-I（or a GLP-1 re-
ceptor agonist）on glycemic control and on an increase 
of b  cell mass is clearly shown17,18,30）. One possible rea-
son may be that the elevation of serum gastrin levels 
by PPI therapy was insufficient to provide a clinically 
observable glucose-lowering effect. In the APPLE 
study, the elevation of serum gastrin levels was ap-
proximately two-fold in the combination therapy group 
creased b  cell mass by neogenesis in ductal cells, we 
performed the current retrospective analysis after the 
completion of the APPLE study. However, there were 
no significant differences in either HbA1c or FPG lev-
els between both groups when examined at more than 
9 months after the completion of the APPLE study. 
The dose and type of diabetic drugs were changed in 
some patients after the completion of the APPLE 
study, and therefore this may have partially influenced 
the results. However, even when the patients were lim-
ited to a subgroup in which all diabetic drugs were not 
changed during the observation period, no significant 
differences in both HbA1c and FPG levels were ob-
served between these groups. Thus, we concluded that 
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who discontinued it after completion of the 3 month 
APPLE study. Although the number of patients who 
continued to take lansoprazole（n＝3）was very small, 
this finding also suggests that the add-on effect of a 
PPI to DPP4-I is not apparent at least clinically in pa-
tients with type 2 diabetes. However it should be noted 
that these 3 patients had had epi-gastric symptoms 
before enrollment in the APPLE study, and that the 
symptoms improved after administration of PPI. This 
may bias the findings because it is possible the treat-
ment increased the appetite of these patients, and 
therefore influenced glycemic control.
In the current study, we also noted that the im-
provement in HbA1c by alogliptin is maintained rela-
tively long-term（approximately 16 months）. This re-
sult appears to support the results of a recently 
published study, in which the improvement on glyce-
mic control by alogliptin lasted long-term（2 years）33）.
In the current study because of the retrospective 
observational analysis, we could not evaluate serum 
gastrin levels, which are important to discuss the pos-
sible legacy effect of PPI together with DPP4-I on gly-
cemic control. This is one of the limitations in this 
study.
In conclusion, based on the results in the APPLE 
study and in the retrospective observation in the cur-
rent study, we conclude that the add-on effect of a PPI 
for DPP4-I on glycemic control in patients with type 2 
diabetes is not apparent clinically. A combination ther-
apy using a new generation PPI, such as vonoprazan 
and a GLP-1 receptor agonist, in patients with type 2 
diabetes might be more effective on glycemic control, 
and future studies are warranted to determine the ef-
fect of this combination therapy.
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